Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CDK1 | P06493 | 17/20 | 0.33 |
| ▸ | CDK2 | P24941 | 17/20 | 0.33 |
| ▸ | KDR | P35968 | 16/20 | 0.33 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.32 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | BCR | P11274 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 3/20 | 0.31 |
| ▸ | CDK4 | P11802 | 2/20 | 0.31 |
| ▸ | CDK7 | P50613 | 2/20 | 0.31 |
| ▸ | CDK9 | P50750 | 2/20 | 0.31 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.31 |
| ▸ | CCND1 | P24385 | 1/20 | 0.31 |
| ▸ | CCNH | P51946 | 1/20 | 0.31 |
| ▸ | STK17B | O94768 | 1/20 | 0.31 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21967071 | 1.00 | MEN1 (0.38) | MEN1KMT2ACDK1CDK2KDR | |
| SCHEMBL16058267 | 0.89 | MEN1 (0.38) | MEN1KMT2ACDK1CDK2KDR | |
| SCHEMBL2722934 | 0.85 | STK17B (0.47) | MEN1KMT2ACDK1CDK2KDR | |
| SCHEMBL20584280 | 0.85 | STK17B (0.47) | MEN1KMT2ACDK1CDK2KDR | |
| SCHEMBL2722937 | 0.85 | STK17B (0.47) | MEN1KMT2ACDK1CDK2KDR | |
| SCHEMBL18495142 | 0.85 | STK17B (0.47) | MEN1KMT2ACDK1CDK2KDR | |
| SCHEMBL21967064 | 0.80 | MEN1 (0.36) | MEN1KMT2ACDK1CDK2KDR | |
| SCHEMBL16057613 | 0.80 | MEN1 (0.36) | MEN1KMT2ACDK1CDK2KDR | |
| SCHEMBL16057611 | 0.80 | MEN1 (0.36) | MEN1KMT2ACDK1CDK2KDR | |
| SCHEMBL29474433 | 0.80 | MEN1 (0.36) | MEN1KMT2ACDK1CDK2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210395259-A1 | CDK INHIBITORS | G1 THERAPEUTICS, INC. (US) | 2021-12-23 | — | — | US | disclosed |
| US-10660896-B2 | Transient protection of normal cells during chemotherapy | GI Therapeutics, Inc. (US) | 2020-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210395259-A1 | CDK INHIBITORS | CDK3, CDK9, CDK6 | MEN1 2275/4885KMT2A 276/4885CDK1 8/4885 |
| US-10660896-B2 | Transient protection of normal cells during chemotherapy | CDK6, CCNC, MCL1 | MEN1 3666/4885KMT2A 513/4885CDK1 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.